Findings

What do systematic reviews say?

3 questions · 3 findings · 2 reviews · HIV/AIDS

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 33.3%Low 2 · 66.7%Moderate 0 · 0%High 0 · 0%

An extended NVP plus ZDV dual regimen administered to infants for 14 weeks vs an extended NVP regimen administered to infants

Infants with Severe Adverse Events · Breastfeeding infants of HIV‐infected mothers

An extended NVP plus ZDV dual regimen administered to infants for 14… may leads to higher infants with any Severe Adverse Events compared with an extended NVP regimen administered to infants (low certainty).

1 finding from 1 review

Antiretroviral interventions for preventing breast milk transmission of HIV 2014 · Cochrane Headline outcomes only
RR 1.66 [1.16, 2.37]
1 study · 2013 participants
Low

An extended NVP plus ZDV dual regimen administered to infants for 14 weeks vs an extended NVP regimen administered to infants

Infants with Probably Related Severe Adverse Events · Breastfeeding infants of HIV‐infected mothers

It is very uncertain whether an extended NVP plus ZDV dual regimen administered to infants for 14… changes infants with Probably Related Severe Adverse Events compared with an extended NVP regimen administered to infants (very low certainty).

1 finding from 1 review

Antiretroviral interventions for preventing breast milk transmission of HIV 2014 · Cochrane Headline outcomes only
RR 1.02 [0.33, 3.15]
1 study · 2013 participants
Very low

d4T vs AZT

Severe adverse events · patients with initial treatment of HIV infection in antiretroviral‐naive individuals

d4T showed no clear difference in severe adverse events compared with AZT (low certainty).

1 finding from 1 review

Stavudine or zidovudine in three‐drug combination therapy for initial treatment of HIV infection in… 2010 · Cochrane Headline outcomes only
RR 1.17 [0.97, 1.4]
9 studies · 1363 participants
Low